tility of thyroid transcription factor-1 as a predictor of immune checkpoint inhibition plus chemotherapy in advanced lung adenocarcinoma.

Not Applicable

• Conditions: Advanced Lung Adenocarcinoma

• Registration Number: JPRN-UMIN000046901
• Lead Sponsor: Kobe university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-01
• Study Completion: 2023-04-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients who have requested not to participate in this study (2) Patients who are judged ineligible by the principal investigator

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To compare progression-free survival (PFS) in patients with TTF-1 positive and negative tumors

Secondary Outcome Measures

Name	Time	Method
To analyze objective response rate (ORR) PFS and overall survival(OS). To compare ORR and OS in patients with TTF-1 positive and negative tumors. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors of Hematoxylin-Eosin Stain-diagnosed lung adenocarcinoma and in patients with TTF-1-diagnosed non-small cell lung cancer (NSCLC) favor adenocarcinoma. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors for each chemotherapy regimen. To compare ORR, PFS and OS in patients for each PD-L1 expression. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors for each PD-L1 expression. To compare TTF-1 positivity rates by histopathology and compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors.